Patient-Based Therapeutics
AcuraStem is a patient-based biotechnology company pioneering how treatments are developed for neurodegenerative diseases — including sporadic ALS and FTD — using our proprietary, best-in-class, disease-modeling platform, iNeuroRx®, the gold standard for discovering novel, effective and broadly-acting treatments.
Patient Focused
learn about our work
Neurodegenerative Disease Areas



Latest News
AcuraStem’s Head of Target Validation, Dr. Wen-Hsuan Chang, presented an update on the company's innovative UNC13A program at the 14th Annual California ALS Research Summit on January 19, 2024
AcuraStem Leverages iNeuroRx® Platform to Drive Innovative SYF2 and UNC13A Treatments Forward Toward Clinical Trial
Agreement enables the development of therapeutics, including AcuraStem’s AS-202 Candidate, an antisense oligonucleotide that suppresses levels of the PIKFYVE kinase